Natera, Inc.
NASDAQ:NTRAMedical - Diagnostics & Research
+$2.23 today
- Market cap
- $41.98B
- Beta
- 1.54
- P/E (TTM)
- -143.0
- EPS (TTM)
- -$1.60
Volume 1.96M
Average 1.41M
NTRA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Natera, Inc.NASDAQ: NTRA
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$45.15M, compared with -$89.78M a year earlier. Trailing-twelve-month EBITDA was -$178.71M.
Context
- EBITDA amounted to 9.6% of revenue in FY2025, up 0.8 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 13 analysts of -$162.66M (+26.2%) for the fiscal year ending Dec 2026, a step up from the -48.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$45.15M+31.0% QoQ
- Last fiscal yearDec 2025
- -$220.54M-48.9% YoY
- LTMJun 2026
- -$178.71M+15.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +49.7% | +76.8% | +27.1 pp |
| 1 year | -48.9% | +26.2% | +75.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (220.54M) USD
- Year-over-year change
- -48.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (220.54M) | -48.9% |
| FY2024 | 2024-12-31 | (148.08M) | +62.8% |
| FY2023 | 2023-12-31 | (397.8M) | +23.6% |
| FY2022 | 2022-12-31 | (520.8M) | -15.3% |
| FY2021 | 2021-12-31 | (451.54M) | — |
EBITDA vs competitors
How NTRA compares with its peers on the latest reported figures
- NTRA's LTM Jun 2026 EBITDA of -$178.71M is the 7th highest of the 8 companies compared; the peer median is -$58.51M.
- Its year-over-year change of +15.6% is the 3rd highest of 8, against a peer median of -16.7%.
- EBITDA amounts to 6.6% of revenue for NTRA, versus a peer median of 23.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $129.77M | +184.0% | — | 23.1% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $50.25M | +362.6% | — | 12.6% |
| LTM Mar 2026 | -$31.22M | +2.8% | — | 54764.9% | |
| LTM Mar 2026 | -$58.51M | -133.4% | — | 18.3% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -$76.43M | -374.1% | — | 16.8% |
| LTM Mar 2026 | -$85.53M | -16.7% | — | 132.6% | |
| LTM Jun 2026 | -$178.71M | +15.6% | — | 6.6% | |
| LTM Mar 2026 | -$334.2M | -423.0% | — | 40.3% | |
| Peer median (excluding NTRA) | -$58.51M | -16.7% | — | 23.1% | |
Competitors are the stored peer set for NTRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 625.49M | 820.22M | 1.08B | 1.7B | 2.31B |
| Cost of Revenue | 318.42M | 456.26M | 589.83M | 673.75M | 810.63M |
| Gross Profit | 307.07M | 363.97M | 492.74M | 1.02B | 1.5B |
| Gross Margin | 49.1% | 44.4% | 45.5% | 60.3% | 64.8% |
| Research & Development | 264.21M | 316.42M | 320.68M | 404.14M | 624.11M |
| Selling, General & Admin | 511.03M | 588.59M | 618.31M | 841.31M | 1.18B |
| Operating Expenses | 775.24M | 905.01M | 938.99M | 1.25B | 1.81B |
| Depreciation & Amortization | 11.25M | 16.7M | 24.1M | 30.97M | 43.48M |
| EBITDA | (451.54M) | (520.8M) | (397.8M) | (148.08M) | (220.54M) |
| EBITDA Margin | -72.2% | -63.5% | -36.7% | -8.7% | -9.6% |
| Operating Income | (468.17M) | (541.04M) | (446.25M) | (222.29M) | (309.91M) |
| Operating Margin | -74.8% | -66.0% | -41.2% | -13.1% | -13.4% |
| Interest Income | 5.38M | 3.54M | 24.35M | 43.25M | 45.89M |
| Interest Expense | 8.31M | 9.32M | 12.64M | 10.69M | 4.07M |
| Other Income / Expenses | (2.92M) | (5.78M) | 11.72M | 32.56M | 41.82M |
| Income Before Tax | (471.1M) | (546.82M) | (434.53M) | (189.73M) | (268.09M) |
| Pre-Tax Margin | -75.3% | -66.7% | -40.1% | -11.2% | -11.6% |
| Income Tax Expense | 618K | 978K | 271K | 695K | (59.93M) |
| Net Income | (471.72M) | (547.8M) | (434.8M) | (190.43M) | (208.16M) |
| Net Margin | -75.4% | -66.8% | -40.2% | -11.2% | -9.0% |
| EPS (Basic) | (5.21) | (5.57) | (3.78) | (1.53) | (1.52) |
| EPS (Diluted) | (5.21) | (5.57) | (3.78) | (1.53) | (1.52) |
| Weighted Avg Shares | 90.56M | 98.41M | 115M | 124.72M | 136.72M |
| Weighted Avg Shares (Diluted) | 90.56M | 98.41M | 115M | 124.72M | 136.72M |
Natera, Inc.
NASDAQ:NTRA
Intrinsic Alpha fair value
Locked
Current Price
$289.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.